Inclusion criteria:

          -  At least 18 years of age at the time of signing the informed consent form.

          -  Patient must have histologically or cytologically confirmed metastatic or locally
             advanced and recurrent NSCLC which is progressing.

          -  Patients eligible for second- or later-line therapy, who must have received an
             antiPD1/PD-L1 containing therapy and a platinum-doublet regimen for locally advanced
             or metastatic NSCLC either separately or in combination. Prior durvalumab is
             acceptable. The patient must have had disease progression on a prior line of
             antiPD1/PD-L1 therapy.

          -  ECOG/WHO performance status of 0 to 1, and a minimum life expectancy of 12 weeks.

          -  Patient must have at least 1 lesion that can be accurately measured. A previously
             irradiated lesion can be considered a target lesion if the lesion has clearly
             progressed.

          -  Evidence of post-menopausal status or negative urinary or serum pregnancy test for
             female pre-menopausal patients.

        Exclusion Criteria:

          -  Patients whose tumour samples have targetable alterations in EGFR and/or ALK are
             excluded. In addition, patients whose tumour samples are known to have targetable
             alterations in ROS1, BRAF, MET or RET, are to be excluded.

          -  Active or prior documented autoimmune or inflammatory disorders.

          -  Active infection including tuberculosis, hepatitis B (known positive HBV surface
             antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus (positive HIV
             1/2 antibodies).

          -  Female patients who are pregnant or breastfeeding, or male or female patients of
             reproductive potential who are not willing to employ effective birth control.

          -  Known allergy or hypersensitivity to any of the study drugs or any of the study drug
             excipients, or history of severe hypersensitivity reactions to other monoclonal
             antibodies.

          -  Patient has spinal cord compression or symptomatic brain metastases.

          -  Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer
             treatment. Patients may receive treatment with bisphosphonates or receptor activator
             of nuclear factor kappa-Β ligand (RANKL) inhibitors for the treatment of bone
             metastases.

          -  history of active primary immunodeficiency